Fig. 4. The effects of calmidazolium (CMZ) on polycystic kidney disease 2-like-1 (PKD2L1) ΔEF current under 16 nM and 100 nM intracellular free calcium concentrations. (A) A full current trace of PKD2L1 (ΔEF) (left) activated by 1 μM of CMZ under 16 nM free Ca2+ and the current (I)–voltage (V) relationship of PKD2L1 (ΔEF) (right) at the basal current amplitude (black) and at the application of 1 μM of CMZ (blue). (B) A full current trace of PKD2L1 (ΔEF) (left) activated by 1 μM of CMZ under 100 nM free Ca2+ and the I–V relationship of PKD2L1 ΔEF (right) at the basal current amplitude (black) and at the application of 1 μM of CMZ (blue). (C) A summarized current amplitude of PKD2L1 (ΔEF) induced by CMZ under 16 nM and 100 nM free Ca2+ (n = 4–5). *p < 0.05, **p < 0.01.
© Korean J Physiol Pharmacol
